Supreme Court Hears 'Machine-Or-Transformation' Test Argument For Patents
This article was originally published in The Gray Sheet
Executive Summary
The Supreme Court on Nov. 9 heard arguments for a case that has been watched closely by test makers, who fear that many diagnostics claims will not be patent eligible if a federal appeals court decision is upheld
You may also be interested in...
Supreme Court Gives Some Relief, But Leaves Open Questions For Dx Patents
Diagnostics and biotech firms praised a June 28 Supreme Court opinion for allowing judges some flexibility in ruling on the patent-eligibility of "process" claims, but patent attorneys warn that many issues remain unsettled
Supreme Court Gives Some Relief, But Leaves Open Questions For Dx Patents
Diagnostics and biotech firms praised a June 28 Supreme Court opinion for allowing judges some flexibility in ruling on the patent-eligibility of "process" claims, but patent attorneys warn that many issues remain unsettled
Patent Suits Trigger Molecular Diagnostics Business Uncertainty
Investment in new molecular diagnostics biomarkers, particularly genetic markers, is suffering due to substantial patent law uncertainties, according to test developers at last week's Biotechnology Industry Organization conference in Chicago